Jagsonpal Pharmaceuticals Secures Shareholders' Approval for Equity Buyback
Jagsonpal Pharmaceuticals Ltd. has announced that its shareholders have approved the proposal to buy back equity shares, marking a significant move aimed at enhancing shareholder value and optimizing the company's capital structure.The Board had originally proposed the buyback on March 12, 2026. The approved proposal allows for the buyback of up to 16 lakh equity shares. The transaction is valued at an aggregate of up to Rs. 40 Crores, with the buyback price set at Rs. 250/- per equity share.
The shareholder endorsement for the buyback reflects continued investor confidence in Jagsonpal's long-term growth prospects, financial discipline, and strategic direction. The company stated that the buyback is designed to optimize capital allocation, improve earnings per share (EPS), and deliver meaningful returns to shareholders.
| Parameter | Detail |
|---|---|
| Total Shares Proposed for Buyback | Up to 16 lakh |
| Buyback Price Per Share | Rs. 250/- |
| Aggregate Value | Up to Rs. 40 Crores |
| Board Proposal Date | March 12, 2026 |
The company affirmed that the buyback aligns with its broader strategy of balancing necessary growth investments with efficient shareholder returns. The detailed timelines and record date for the proposed buyback will be communicated in due course.
About Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited is a leading presence in the Indian pharmaceutical sector, boasting a history spanning over four decades. The company maintains a robust and diverse portfolio of drugs, with a primary focus on Gynaecology, Orthopaedics, Dermatology, and Child-care segments.Over the years, Jagsonpal has established multiple brands that hold market-leading positions within their respective segments. The company has cultivated a strong niche by possessing over 20 brands that are categorized among the Top 5 brands within their molecule category. It operates with an extensive pan-India presence and an experienced sales team consisting of over 1000 professionals.
Jagsonpal Pharmaceuticals Limited is listed on the National Stock Exchange Limited (JAGSNPHARM) and the Bombay Stock Exchange (Scrip code: 507789), and is headquartered in Delhi.
JAGSNPHARM Stock Price Movement
Jagsonpal Pharmaceuticals Limited shares slipped by 1.62% on Friday, closing at ₹198.75. The stock traded with a notable volume of 123,410 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.